SUPN Overview

Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its neuroscience portfolio includes treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. Its products include Qelbree, GOCOVRI, APOKYN, Trokendi XR, Oxtellar XR, ZURZUVAE, ONAPGO, XADAGO, and MYOBLOC. Qelbree is a non-stimulant product indicated for the treatment of ADHD in adults and pediatric patients six years and older. GOCOVRI extended-release capsules are medicine indicated for the treatment of dyskinesia in patients with PD receiving levodopa-based therapy. It is also involved in developing product candidates in neurology and psychiatry, including SPN-817 (huperzine A), SPN-820 (NV-5138), and SPN-443.

Wall Street analysts forecast SUPN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SUPN is61.33 USD with a low forecast of 55.00 USD and a high forecast of 65.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Supernus Pharmaceuticals Inc revenue for the last quarter amounts to 211.57M USD, increased 21.48

Supernus Pharmaceuticals Inc. EPS for the last quarter amounts to -0.07 USD, decreased -125.93

Supernus Pharmaceuticals Inc (SUPN) has 778 emplpoyees as of April 20 2026.

Today SUPN has the market capitalization of 2.96B USD.